**Supplementary table 1. Subgroup analysis for the change from baseline in DAS28-ESR at week 24**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | | LBEC0101 | | ETN-RP | |
| n | Mean ± SD | n | Mean ± SD |
| Overall | | 164 | −2.93±1.11 | 165 | −2.89±1.21 |
| Country | Japan | 85 | −2.97±1.13 | 86 | −2.88±1.21 |
| Korea | 79 | −2.89±1.10 | 79 | −2.91±1.23 |
| Previous use of a biological DMARD | Yes | 28 | −2.85±1.21 | 26 | −3.28±1.51 |
| No | 136 | −2.95±1.10 | 139 | −2.82±1.14 |
| Baseline DAS28-ESR | < median | 92 | −2.56±0.90 | 72 | −2.52±1.02 |
| ≥ median | 72 | −3.41±1.18 | 93 | −3.18±1.28 |
| Baseline MTX dose | ≤10 mg/week | 82 | −3.03±1.18 | 88 | −2.93±1.19 |
| >10 mg/week | 82 | −2.84±1.03 | 77 | −2.85±1.24 |

Abbreviations: ETN-RP, etanercept reference product; DAS28-ESR, disease activity score in 28 joints based on erythrocyte sedimentation rate; DMARD, disease-modifying antirheumatic drug; SD, standard deviation.